FIG. 5.

Possible pharmacological targets for SSBP, including ENaC, ROS, IsoLG, and NLRP3 inflammasome. NF-κB inhibitors and NLRP3 inflammasome inhibitor MCC950 had promising results in murine models of DOCA/salt-induced hypertension. ELA also inhibits NADPH oxidase/ROS-mediated NLRP3 inflammasome activation in animal studies. While anakinra was shown to have antihypertensive effects in murine models, human studies found no effect of canakinumab on blood pressure. DOCA, deoxycorticosterone acetate; ELA, ELABELA. Color images are available online.